Entrada Therapeutics announced Phase 1/2 trial results showing only a 2.36% increase in dystrophin production, far below competitive levels. Despite calling the results "positive," the market reacted negatively, causing the stock to drop 57.27% on May 7, 2026. Pomerantz LLP is investigating potential securities fraud and unlawful practices by Entrada and its executives. Investors affected are encouraged to contact the law firm as a class action may follow.
Duke Robotics Corp. announced a $9.2 million underwritten public offering of 1,125,000 units priced at $8.20 each, including common stock and warrants. The company plans to use the proceeds for R&D, sales expansion, marketing, business development, p...
GoldMining Inc. held its 2026 annual meeting on May 14, where a quorum of 27.04% of shares voted. All six director nominees proposed by management were elected with strong majority support, each receiving over 90% of votes. Shareholders also approved...
Weyerhaeuser Company announced a quarterly base cash dividend of $0.21 per common share, payable on June 22, 2026, to shareholders of record as of June 5, 2026. The company aims to return 75-80% of its annual Adjusted Funds Available for Distribution...
Kirby McInerney LLP is investigating Zillow Group for potential violations of federal securities laws related to premature revenue recognition and an alleged unlawful agreement with Redfin. Zillow's stock dropped following reports of revenue recognit...
Calix, Inc. is under investigation by law firm Kirby McInerney LLP for potential violations of federal securities laws following its Q1 2026 earnings report. The company reported a decline in non-GAAP gross margin and issued cautious guidance for the...
